/

Società

By

Non verificato

Byondis B.V.

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaOncologiaPubblicità/Marketing/Media/Comunicazione

5 comunicati stampa

Guarda tutti i comunicati

17/05/2026

Farmaceutica

Pubblicità/Marketing/Media/Comunicazione

Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development

Fonte

Emittente

1.00

0

17/04/2026

Eventi

Oncologia

Salute

Scienza

Farmaceutica

Biotecnologia

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

Fonte

Emittente

1.00

0

03/06/2025

Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors

Fonte

Emittente

1.00

0

24/03/2025

Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer

Fonte

Emittente

1.00

0

19/11/2024

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0